Read Trending Stories
- » Ultimate Market Recap: Talbots Tanks, Facebook Fiasco Continues
- » Are Facebook Losses Bigger Than Initially Thought?
- » Consumer Business Recap: Toyota Needs Emerging Markets, Wal-Mart's Express Update
- » Consumer Biz Recap: Talbots CRASHES HARD, Time Warner Eyes Sports Website
- » Your Cheat Sheet to Apple's Week of Stock Moving News
Today's Trending Stocks
Click a Company to Research Now:
- Bank of America (BAC)
- Apple . (AAPL)
- Facebook (FB)
- AT&T (T)
- Nokia (NOK)
- Delcath Systems (DCTH)
- Mentor Graphics Corp (MENT)
- Complete Genomics (GNOM)
CIGNA Corporation(NYSE:CI): Cigna shares defended on today’s weakness at Leerink.
Intuitive Surgical, Inc.(NASDAQ:ISRG): Collins Stewart confirmed with Intuitive Surgical (NASDAQ:ISRG) management that the Japanese Ministry of Health indicated da Vinci prostatectomy is scheduled to be reimbursed beginning in April. The firm expects Intuitive Surgical, along with its Japanese partner Johnson and Johnson (NYSE:JNJ), to pursue reimbursement for additional procedures. Collins Stewart says it is now more confident in Intuitive Surgical’s long-term growth story and keeps a Buy rating on the stock. Note Lazard Capital said this morning in a note to investors that Japan is moving towards complete da Vinci prostatectomy reimbursement.
ShoreTel, Inc.(NASDAQ:SHOR): ShoreTel shares defended at JP Morgan
Vertex Pharmaceuticals Incorporated(NASDAQ:VRTX): Brean Murray is cautious ahead of Vertex’s report tonight and believes the company could report Incivek sales of $440M below the Street estimate of $470M, which will result in lower 2012 guidance.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com
To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com
Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!
Do You Want More Profits? Wall St. Cheat Sheet Premium newsletter subscribers have been crushing the markets with winning stock picks.
Click here now for your FREE trial to our acclaimed flagship newsletter:
